506640 ZR2

ZR2 Bioenergy Share Price

 
Stock touched 52W low

 

Start SIP in ZR2

Start SIP
ZR2 Bioenergy live price: ₹102.9. It opened at ₹120 vs previous close ₹114; intraday high/low: ₹123/₹103. The 50 & 200 DMA stand at ₹171.26/₹269.83.

ZR2 Bioenergy Performance

  • Low
  • ₹103
  • High
  • ₹123
  • 52 Week Low
  • ₹103
  • 52 Week High
  • ₹437
  • Open Price₹120
  • Previous Close₹114
  • Volume3,320
  • 50 DMA₹171.26
  • 100 DMA₹220.10
  • 200 DMA₹269.83

Investment Returns

  • Over 1 Month -33.78%
  • Over 3 Month -63.94%
  • Over 6 Month -75.45%
  • Over 1 Year -67.74%

Smart Investing Starts Here Start SIP with ZR2 Bioenergy for Steady Growth!

Invest Now

ZR2 Bioenergy Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 40
  • PEG Ratio
  • 0.1
  • Market Cap Cr
  • 37
  • P/B Ratio
  • 0.3
  • Average True Range
  • 16.14
  • EPS
  • -
  • Dividend Yield
  • 0.1
  • MACD Signal
  • -13.1
  • RSI
  • 25.26
  • MFI
  • 16.47

ZR2 Bioenergy Financials

ZR2 Bioenergy Technicals

EMA & SMA

Current Price
₹102.90
-11.4 (-9.97%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹137.40
  • 50 Day
  • ₹171.26
  • 100 Day
  • ₹220.10
  • 200 Day
  • ₹269.83

Resistance and Support

109.58 Pivot Speed
  • R3 136.32
  • R2 129.63
  • R1 116.27
  • S1 96.22
  • S2 89.53
  • S3 76.17

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

ZR2 Bioenergy Ltd has an operating revenue of Rs. 1.49 Cr. on a trailing 12-month basis. An annual revenue growth of 12% is good, Pre-tax margin of 14% is healthy, ROE of 0% is poor and needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. From an O'Neil Methodology perspective, the stock has an EPS Rank of 33 which is a POOR score indicating inconsistency in earnings, a RS Rating of 1 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at E which indicates heavy supply, Group Rank of 85 indicates it belongs to a poor industry group of Chemicals-Specialty and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment. Please note that this is a thinly traded stock.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

ZR2 Bioenergy Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-14 Quarterly Results
2025-09-03 Final Dividend
2025-08-13 Quarterly Results
2025-05-29 Audited Results & Others Inter-alia, to consider 1. Resignation & Appointment of Company Secretary and Compliance Officer. 2. Appointment of Ritika Agrawal & Associates as new Secretarial Auditor. 3. Other business matters. per share(10%)Final Dividend
2025-05-15 Others Inter alia, to consider and approve 1. The appointment of Company Secretary and Compliance Officer in the Company. per share(10%)Final Dividend
Date Purpose Remarks
2025-09-10 FINAL Rs.0.10 per share(10%)Final Dividend
Date Purpose Remarks
2022-05-27 Split Re.0.00 split from rs. 10/- to Re. 1/-.

ZR2 Bioenergy F&O

ZR2 Bioenergy Shareholding Pattern

61%
0%
0%
0%
0.05%
37.1%
1.85%

About ZR2 Bioenergy

  • NSE Symbol
  • ZR2
  • BSE Symbol
  • 506640
  • Chairperson & Managing Director
  • Mr. Jimmy Olsson
  • ISIN
  • INE218N01021

Similar Stocks to ZR2 Bioenergy

ZR2 Bioenergy FAQs

ZR2 Bioenergy share price is ₹102 As on 15 March, 2026 | 21:13

The Market Cap of ZR2 Bioenergy is ₹36.7 Cr As on 15 March, 2026 | 21:13

The P/E ratio of ZR2 Bioenergy is 40 As on 15 March, 2026 | 21:13

The PB ratio of ZR2 Bioenergy is 0.3 As on 15 March, 2026 | 21:13

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23